For Q1 FY2026 ended March 31, 2026, Crescent Biopharma reported revenue of $1.039 million and a net loss of $23.283 million, a 53.7% increase in net loss year-over-year. Operating loss was $24.729 million, up 73.9% from the prior year. The company held $189.163 million in cash and $183.847 million in equity, with no long-term debt.
•Revenue was $1.039 million for the quarter.
•Net loss widened to $23.283 million, a 53.7% increase from the prior year.
•Operating loss increased 73.9% to $24.729 million.
•Cash and cash equivalents stood at $189.163 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Crescent Biopharma, Inc., a biotechnology company researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. Founded in 2024, the company is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates in the United States. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody currently in Phase 3 clinical trials for treating solid tumors. The company also has earlier-stage candidates CR-002 and CR-003. Crescent Biopharma has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. and was founded in 2024, headquartered in Waltham, Massachusetts.
Where is Crescent Biopharma listed and what currency does it trade in?
Crescent Biopharma, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CBIO. Its shares are traded in United States Dollars (USD). The company is headquartered in Waltham, Massachusetts, and operates primarily in the United States.
What sector and industry does Crescent Biopharma belong to?
Crescent Biopharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative cancer therapies, including bispecific antibodies for solid tumors. The company's work involves clinical-stage drug development, with its lead candidate CR-001 in Phase 3 trials.
Where is Crescent Biopharma headquartered and what markets does it serve?
Crescent Biopharma is headquartered in Waltham, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its operations being based in the country. Its strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. suggests a collaborative approach to developing oncology therapeutics, potentially extending its reach to global markets, though its core focus remains on the United States.
What is Crescent Biopharma's business model and how does it generate revenue?
Crescent Biopharma's business model centers on researching and developing cancer therapy candidates, with the goal of advancing them through clinical trials and ultimately commercializing them. The company's pipeline includes CR-001, a bispecific antibody in Phase 3 trials for solid tumors, as well as earlier-stage candidates CR-002 and CR-003. Revenue generation typically involves licensing deals, partnerships, and potential future product sales. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, which may include milestone payments and royalties. As a clinical-stage biotechnology firm, it likely does not yet have approved products generating significant revenue.